OSI SYSTEMS INC annual report, FY2022

OSI Systems, Inc. Fiscal 2022 Form 10-K Summary

Business context and reporting period

The filing is an annual report for the fiscal year ended June 30, 2022, filed August 19, 2022. The request metadata references “2021 Q4,” but the filing reports full-year fiscal 2022 results and comparative fiscal 2021 results. OSI Systems designs and manufactures specialized electronic systems and components through three segments: Security, Healthcare, and Optoelectronics and Manufacturing.

Security: inspection systems, detection equipment, software integration, and turnkey screening services; 56% of fiscal 2022 revenue.
Healthcare: patient monitoring, cardiology, remote monitoring, connected care systems, supplies, and accessories; 17% of revenue.
Optoelectronics and Manufacturing: optoelectronic devices, flexible circuits, and electronics manufacturing services; 27% of revenue.

Financial performance and key metrics

Metric	Fiscal 2022	Fiscal 2021	Change
Revenue	$1,183.2 million	$1,146.9 million	+3.2%
Gross profit	$424.4 million	$419.9 million	+$4.5 million
Gross margin	35.9%	36.6%	-0.7 percentage points
Income from operations	$121.7 million	$115.4 million	+5.5%
Net income	$115.3 million	$74.0 million	+55.8%
Diluted EPS	$6.45	$4.03	+60.0%
Cash flow from operations	$63.8 million	$139.1 million	-$75.3 million

Security revenue increased 5% to $663.2 million, including approximately $20 million of additional product revenue and $10 million of additional service revenue.
Healthcare revenue declined 3% to $205.7 million. Cardiology and service, supplies, and accessories grew, but patient-monitoring revenue declined approximately $16.1 million following elevated COVID-19-related demand in fiscal 2021.
Optoelectronics and Manufacturing revenue increased 4% to $314.3 million, driven by approximately $10 million of optoelectronics growth and $3 million of contract-manufacturing growth.
Operating expenses declined 1% to $302.7 million. SG&A declined 2%, while research and development increased 11% to $59.6 million.
The effective tax rate declined to 17.7% from 24.9%, partly due to a $7.0 million net discrete tax benefit, compared with $1.2 million in fiscal 2021.
Other income of $27.4 million primarily reflected the gain on the March 2022 sale-leaseback of the Hawthorne property.

Liquidity, debt, and capital allocation

Cash and cash equivalents were $64.2 million at June 30, 2022, compared with $80.6 million one year earlier. Approximately 78% was held by foreign subsidiaries.
The $63.8 million of operating cash flow was substantially below fiscal 2021, primarily because of higher inventory, lower accounts payable, and reduced customer advances.
Capital expenditures were $14.9 million, acquisitions used $14.1 million, and intangible and other asset purchases were $15.6 million.
OSI repurchased 1.295 million shares during fiscal 2022 and used $111.6 million for share repurchases. An additional $19.4 million was paid for taxes related to net settlement of equity awards.
Total outstanding borrowings and debt were approximately $353.4 million at June 30, 2022, including $60.0 million under the revolving facility, $50.0 million under the term loan, and $242.3 million of convertible notes due September 1, 2022.
The amended credit facility totals $750 million and matures in December 2026. Including available borrowing capacity and letters of credit, total available capacity under the facilities was approximately $561.5 million. The company was in compliance with its financial covenants.
Management expects available cash, credit facilities, and operating cash flow to fund operations and the convertible-note maturity for at least the next 12 months. No cash dividends are planned for the foreseeable future.

Material changes and unusual items

Gross margin decreased because of unfavorable mix, stronger growth in the lower-margin Optoelectronics and Manufacturing segment, weaker Healthcare mix, and higher component, freight, and logistics costs.
Operating income improved despite margin pressure because of higher revenue and lower operating expenses.
The $27.4 million Hawthorne sale-leaseback gain materially increased pre-tax income and net income; it is not representative of recurring operating performance.
Fiscal 2022 impairment, restructuring, and other charges totaled $7.5 million, including $5.1 million of legal charges, $1.2 million of employee termination costs, $1.0 million of software impairments, and $0.3 million of acquisition-related costs.
OSI acquired two Security businesses for approximately $15.1 million in aggregate, plus potential contingent consideration of up to approximately $25 million for the larger transaction.
The company early adopted ASU 2020-06 for its convertible notes, increasing retained earnings by approximately $19 million, reducing common stock by approximately $27 million, and reducing subsequent non-cash interest expense.
Backlog increased to $1.232 billion from $1.076 billion. Approximately $514 million was not reasonably expected to be fulfilled in fiscal 2023; management cautions that backlog is not a reliable forecast of future revenue.
The company reported effective disclosure controls and effective internal control over financial reporting. Moss Adams LLP issued unqualified audit opinions.

Guidance, outlook, commentary, and risks

The filing does not provide formal quantitative revenue or earnings guidance. Management expects available liquidity and borrowing capacity to support operations, capital requirements, and the September 2022 convertible-note maturity, but emphasizes that future requirements depend on acquisitions, capital expenditures, litigation, repurchases, research and development, covenant compliance, and capital-market conditions.

COVID-19 continued to cause supply-chain disruption, labor shortages, transportation constraints, facility restrictions, delayed deliveries, and possible delays in customer acceptance and revenue recognition.
Inflation and higher interest rates are increasing materials, freight, labor, and borrowing costs and could compress margins or reduce customer purchasing.
The Russia-Ukraine conflict and related sanctions create geopolitical, trade, logistics, currency, and cybersecurity risks. Healthcare research and development activities in Ukraine were somewhat affected.
Security and Healthcare demand depends partly on government budgets, procurement timing, airport and border activity, healthcare capital spending, reimbursement conditions, and contract renewals.
The company faces supply concentration, including certain single-vendor components, and does not have redundant manufacturing capability for every product or component.
Government contracts may be renegotiated or terminated for convenience, and noncompliance with procurement, export-control, anti-bribery, or other regulations could result in penalties, suspension, debarment, or loss of business.
Medical-device regulation, including FDA requirements and the European Union Medical Devices Regulation, could increase compliance costs, delay product clearances, or limit market access.
Cyberattacks, ransomware, data-security incidents, product defects, recalls, litigation, environmental claims, and an ongoing company-wide ERP implementation could adversely affect operations and financial reporting.
Potential contingent acquisition payments had a maximum remaining amount of $52.2 million at June 30, 2022. Legal and environmental matters were not accrued because management considered adverse outcomes possible but not probable and reasonably estimable.

Facts investors should verify

Verify the company’s ability to refinance or repay the $242.3 million convertible-note principal due September 1, 2022 and review subsequent filings for the actual settlement.
Assess whether fiscal 2022 earnings benefited materially from the nonrecurring $27.4 million property sale-leaseback gain and lower convertible-debt amortization.
Monitor operating cash flow, inventory levels, customer advances, and working-capital conversion after the substantial decline in cash generation.
Evaluate whether supply-chain, inflation, labor, freight, and foreign-exchange pressures continue to reduce gross margins.
Review Security backlog conversion, customer acceptance milestones, cancellations, and the portion expected after fiscal 2023.
Review subsequent disclosures regarding legal investigations, class-action litigation, government contracts, contingent consideration, and regulatory compliance.
Confirm the status and cost of the ERP implementation, the EU medical-device transition, and cybersecurity incidents or controls.